Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy Phase 3b

NCT01728077 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.

NCT NCT01728077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01728077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy Phase 3b
Lead sponsor
UCB Pharma SA
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
August 31, 2016
Enrollment
26 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy